Clinical application and mechanism exploration of prone position dynamic angle adjustment combined with oscillatory ventilation technology in optimizing ventilation blood flow ratio in patients with acute respiratory distress syndrome (ARDS)

Prone dynamic angle adjustment combined with oscillation technology for improving ARDS Clinical application of blood flow ventilation ratio

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500108503

Enrollment

Unknown

Registered

2025-09-01

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome

Interventions

Control group:Traditional prone position treatment

Experimental group:Prone position dynamic angle adjustment: The daily prone position time should be >= 8 hours, and the position angle should be adjusted every 2 hours (0 ° ? 10 ° ? 20 ° ? 30 ° cycle)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Moderate to severe ARDS that meets the Berlin criteria, with acute onset (onset time = 5 cmH 2 O; no evidence of cardiogenic pulmonary edema. 2. Age range: 18-75 years old. 3. Mechanical ventilation requirements: invasive mechanical ventilation has been accepted for = 72 hours. 4. Hemodynamic stability: Mean arterial pressure (MAP) >= 65 mmHg; No severe arrhythmia or acute myocardial infarction. 5. The patient or legal representative voluntarily participates and signs a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Prone position contraindications: spinal instability, pelvic/chest wall fractures; Severe intracranial hypertension (ICP>20 mmHg) or open traumatic brain injury; Recent (40 kg/m ²) 2. Taboos for shaking sputum discharge: rib fractures, subcutaneous emphysema, and undirected pneumothorax; Coagulation dysfunction (INR>2.0 or PLT<50 × 10 ?/L); Active pulmonary hemorrhage or intrathoracic tumor. 3. Other exclusion scenarios: End stage disease (expected survival time<7 days); Combined severe liver and kidney failure (Child Pugh grade C or eGFR<15 mL/min); Immunosuppressive state (such as HIV/AIDS, long-term high-dose corticosteroids); Previous participation in other interventional clinical trials (<30 days).

Design outcomes

Primary

Measure	Time frame
Oxygenation function;Ventilation/perfusion ratio;Pulmonary mechanics parameters;	—

Secondary

Measure	Time frame
Clinical outcomes and optimization of medical resources;Feasibility and safety of intervention measures;Construction of a prediction model for physiological function recovery;	—

Countries

China

Contacts

Public ContactLi Lianchi

West China Hospital of Sichuan University

305848668@qq.com+86 138 8024 7512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026